LeMaitre Vascular, Inc. (LMAT) Guidance & Earnings Results

On 2026-08-04 LeMaitre Vascular, Inc. raised guidance: "FY2026 sales midpoint $276.3M (+11% organic), gross margin 72.4%, EPS $2.89 (+15%, +21%…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

LMATLeMaitre Vascular, Inc.Follow LMAT — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 1.9B
P/E TTM: 29.6
Dividend yield: 1.1%
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	FY2026 sales midpoint $276.3M (+11% organic), gross margin 72.4%, EPS $2.89 (+15%, +21% adj.) · full year
5 May 26	Raised	Full-year sales guidance midpoint $280M (+12%), EPS $3.00 (+19%, +26% adj.) · full year
25 Feb 26	Raised	FY2026 sales $280M (+12%), operating income $77.8M (+21% adjusted), EPS $2.91 (+22% adjusted) · full year
6 Nov 25	Raised	Full-year sales midpoint $248M (+13% organic), operating income midpoint $67.1M (+28%), EPS midpoint $2.51 (+30%) · full year
5 Aug 25	Raised	FY2025: Sales $248-254M (mid $251M, +14%, +15% organic); Gross margin 69.7%; Op. income $58.8-63.0M (mid $60.9M, +17%); Op. margin 24%; EPS $2.23-2.37 (mid $2.30, +19%). Q3 2025: Sales $61.2-63.2M (mid $62.2M, +13%, +15% organic); Gross margin 69.7%; Op. income $14.4-15.8M (mid $15.1M, +14%); EPS $0.54-0.59 (mid $0.57, +16%). · full year

LeMaitre Vascular, Inc. — questions

What guidance did LeMaitre Vascular, Inc. give?: On 2026-08-04: "FY2026 sales midpoint $276.3M (+11% organic), gross margin 72.4%, EPS $2.89 (+15%, +21% adj.)"
When does LeMaitre Vascular, Inc. report earnings?: LeMaitre Vascular, Inc.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from LeMaitre Vascular, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.